Effect of omega 3 on major adverse cardiac effects after PCI

Effect of omega 3 on inflammatory marker, hs-CRP, and 30-days major adverse cardiac effects (MACE) after percutaneous coronary intervention (PCI) in chronic kidney disease patients (CKD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014122720441N1

Enrollment

Registered

2015-03-01

Start date

2015-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart disease. Atherosclerosis

Interventions

Intervention 1: Standard treatment before PCI (clopidogrel+heparin+ASA) plus 3gr single dose of omega 3 soft gel at least 12 hours before PCI. Intervention 2: ?Standard drug treatment before PCI (clo

Treatment - Drugs

Standard treatment before PCI (clopidogrel+heparin+ASA) plus 3gr single dose of omega 3 soft gel at least 12 hours before PCI

?Standard drug treatment before PCI (clopidogrel+heparin+ASA)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Informed consent form; NSTE-ACS candidate for elective PCI; treatment with ASA at least 5 days before PCI; CKD patients (GFR ? 60 ml/min) Exclusion criteria: CABG during last 3 months; treatment with glycoprotein IIb/IIIa inhibitors during PCI; treatment with bivalirudine during PCI; sensitivity or tolerance to ASA or Clopidogrel; unsatisfactory PCI; sever active bleeding; sever adverse effects to drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Highly sensitive C reactive protein. Timepoint: 24 hours after PCI. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Major Adverse Cardiac Effect (MACE). Timepoint: 30 days after PCI. Method of measurement: Following patients by phone.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzaneh Foroughnia

Shiraz University of Medical Sciences

farzanehforoughinia@yahoo.comforoughinia@sums.ac.ir+98 71 3242 4206

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026